Skip to content

The Actual News

Stay informed without the news wearing you out.

Daily pill doubles survival time for pancreatic cancer patients

Daily pill doubles survival time for pancreatic cancer patients

Summary

A new daily pill called daraxonrasib has nearly doubled the survival time for patients with advanced pancreatic cancer by targeting a common mutation in the cancer cells. In a large international trial, patients taking daraxonrasib lived on average 13.2 months compared to 6.6 months for those on chemotherapy, and they experienced fewer severe side effects.

Key Facts

  • Daraxonrasib is a pill that blocks the mutated KRAS gene found in over 90% of pancreatic tumors.
  • The drug was tested in a trial with 500 patients from North America, Europe, and Asia.
  • Patients on daraxonrasib survived on average 13.2 months, while those on chemotherapy survived 6.6 months.
  • The pill caused fewer serious side effects (43.6%) than chemotherapy (57.5%).
  • Pancreatic cancer is often diagnosed late and is very difficult to treat, with more than half of patients dying within three months after diagnosis.
  • Around 11,500 people are diagnosed with pancreatic cancer each year in Britain, with about 10,200 deaths annually.
  • Symptoms of pancreatic cancer can include jaundice, itching, dark urine, pale stools, weight loss, tiredness, and fever, but these signs often appear late or resemble other illnesses.
  • The trial results were presented at a major cancer conference in the United States, highlighting this treatment as a major advance for patients with metastatic pancreatic cancer.
Read the Full Article

This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.

The week's biggest stories, one calm email every Monday.